GSK loses out to Pfizer in supplying domestic market with RSV vaccine

2024-06-24

疫苗上市批准临床研究

GSK lost out to a key rival in the battle to supply respiratory syncytial virus (RSV) vaccines for the UK’s upcoming immunisation programme, dealing a blow to the drugmaker on its home turf. In documents published Monday, the UK Health Security Agency said that Pfizer’s RSV shot Abrysvo has been chosen ahead of GSK’s Arexvy.

The UK’s immunisation programme will kick off at the start of September, targeting adults aged between 75 years and 79 years, as well as pregnant women to protect their infants. The Health Security Agency noted that Abrysvo will be used in both groups.

Pfizer’s shot is approved for use in the two groups, while GSK’s jab is only authorised for use in older adults. The two products carry list prices of $295 and $280, respectively, in the US, although discounts are typically offered to government tenders, such as for the UK’s programme.

According to Bloomberg – citing the contents of a redacted contract published earlier this month – Pfizer will supply over 3.5 million doses of Abrysvo for older adults and more than 1.4 million doses to pregnant mothers in England and Northern Ireland over the next two years. While further details were not disclosed, a Pfizer spokesperson said that the contract followed a competitive tender process.

GSK’s vaccine has so far been leading the sales battle of the RSV vaccines, bringing in revenue of £1.2 billion ($1.5 billion) last year, compared with $890 million for Pfizer’s shot.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构